Pyxis Reports Durable MICVO Data in Head and Neck Cancer
BOSTON, Massachusetts, USA | November 18, 2026 Pyxis Oncology, Inc. has announced updated Phase 1 clinical data for its...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 Clinical Trial Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
BOSTON, Massachusetts, USA | November 18, 2026 Pyxis Oncology, Inc. has announced updated Phase 1 clinical data for its...
BOSTON — September 9, 2026 Pyxis Oncology, Inc. announced positive updated data from its ongoing Phase 1 monotherapy study...
